3mo
2mo
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39941348/
The global prevalence of obesity and type 2 diabetes mellitus (T2D) has risen in parallel over recent decades. Most individuals diagnosed with T2D exhibit adiposopathy-related diabetes (ARD), a condition characterized...
Adipocentric treatment paradigm for type 2 diabetes emphasizes weight loss, visceral fat reduction, and cardiometabolic benefits using GLP-1, SGLT2 inhibitors, or surgery, surpassing traditional glucocentric approaches.
2mo
Type 2 Diabetes and the Multifaceted Gut-X Axes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40871736/
Type 2 diabetes (T2D) is a complex metabolic disease characterized by chronic hyperglycemia due to insulin resistance and inadequate insulin secretion. Beyond the classically implicated organs, emerging evidence highlights the...
Type 2 diabetes pathogenesis involves multiple Gut-X axes linking microbiota, metabolites, and hormones with pancreas, liver, kidneys, and endocrine systems. Targeting gut-derived pathways offers therapeutic potential for glycemic control and complications.
2mo
Type 2 diabetes, heart failure and the treatment of their comorbidity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39641257/
Both heart failure and type 2 diabetes are prevalent conditions and share similar pathogenesis, risk factors, and treatment medications. This review aims to inform clinical practice by summarizing the interaction...
This review highlights shared mechanisms of heart failure and type 2 diabetes, emphasizing novel drugs like SGLT2 inhibitors and GLP-1 receptor agonists, their benefits, and the importance of individualized, evidence-based therapy.
3mo
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39404426/
Low-grade inflammation (LGI) represents a key driver of type 2 diabetes (T2D) and its associated cardiovascular diseases (CVDs). Indeed, inflammatory markers such as hs-CRP and IL-6 predict the development of...
Low-grade inflammation drives type 2 diabetes and cardiovascular risk via immune, metabolic, and epigenetic mechanisms. Targeted therapies, including GLP-1RA and colchicine, show potential in reducing residual inflammatory burden.